Mo1530 Efficacy of a 2% Rebamipide Solution As a Novel Submucosal Injection Agent for Gastric Endoscopic Submucosal Dissection

Ai Fujimoto,Yasutoshi Ochiai,Osamu Goto,Toshihiro Nishizawa,Rieko Nakamura,Tadateru Maehata,Satoshi Kinoshita,Seiji Sagara,Toshio Uraoka,Naohisa Yahagi
DOI: https://doi.org/10.1016/j.gie.2015.03.860
IF: 10.396
2015-01-01
Gastrointestinal Endoscopy
Abstract:Rebamipide is a safe and widely used medication for oral administration to patients with gastritis or gastric ulcers. A combination therapy of proton pump inhibitor (PPI) and rebamipide was reported to effectively promote ulcer healing after endoscopic submucosal dissection (ESD). Complications from ESD, however, may prevent patients from commencing the prescribed course of three oral ingestions per day immediately after an ESD is performed. Aims: In this preclinical study we developed a novel 2% rebamipide solution for submucosal injection agent in ESD, used it for ESD experimentally in porcine stomachs,and examined the quality and speed of ulcer healing after the procedure.
What problem does this paper attempt to address?